In vivo evaluation of efficacy and safety of Coagulansin-A in treating arthritis – PubMed Black Hawk Supplements

Abstract

The current study aimed to determine the safety and efficacy of Coag-A through in vivo analysis in CFA induced mice model. Treatment of CFA induced arthritis in mice with Coagulansin-A (10 mg/kg i.p. daily for 28 days), a withanolide obtained from Withania coagulans, as well as standard drug treatment with Dexamethasone (5 mg/kg i.p) was provided. The effect of Coag-A on body weight, relative organ weight, hematology, serum biochemistry, survival rate, oxidative stress markers, and antioxidant enzymes was evaluated. The liver and kidney histopathology were also assessed to ascertain its safety profile. Treatment of arthritic mice with Coag-A considerably improved body weight, relative organ weight of liver, kidney, and spleen, ameliorated hematology and serum biochemistry, and increased survival and antioxidant potential. Coag-A was found to be safer with fewer adverse effects showing hepato-protective, nephroprotective, and anti-inflammatory effect. It also significantly (p < 0.001) improved histopathology of CFA-induced mice when compared with Dexa. In conclusion, compared to dexamethasone, Coag-A has demonstrated a greater therapeutic benefit and fewer side effects in the treatment of arthritis against the CFA-induced model.

Keywords: Antioxidant; Arthritis; CFA-Induced Arthritis; Coagulansin-A; Dexamethasone; Withanolides.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no competing interests.

Similar articles

• Anti-inflammatory and anti-arthritic potential of Coagulansin-A: in vitro and in vivo studies.

  Naz S, Mazhar MU, Yadav U, Ali HA, Khasawneh F, Ihsan-Ul-Haq, Tipu MK, Zhu L. Naz S, et al. Inflammopharmacology. 2024 Apr;32(2):1225-1238. doi: 10.1007/s10787-024-01432-z. Epub 2024 Feb 27. Inflammopharmacology. 2024. PMID: 38411787

• Immunostimulant, hepatoprotective, and nephroprotective potential of Bacillus subtilis (NMCC-path-14) in comparison to dexamethasone in alleviating CFA-induced arthritis.

  Mazhar MU, Naz S, Zulfiqar T, Khan JZ, Ghazanfar S, Tipu MK. Mazhar MU, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3275-3299. doi: 10.1007/s00210-023-02814-w. Epub 2023 Nov 6. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37930392

• Coagulansin-A improves spatial memory in 5xFAD Tg mice by targeting Nrf-2/NF-κB and Bcl-2 pathway.

  Shal B, Khan A, Ullah Khan A, Ullah R, Naveed M, Ali G, Ul Islam S, Ul Haq I, Mirza B, Khan S. Shal B, et al. Int Immunopharmacol. 2022 Aug;109:108860. doi: 10.1016/j.intimp.2022.108860. Epub 2022 May 19. Int Immunopharmacol. 2022. PMID: 35598479

• Phytochemistry, Food Application, and Therapeutic Potential of the Medicinal Plant (Withania coagulans): A Review.

  Khan MI, Maqsood M, Saeed RA, Alam A, Sahar A, Kieliszek M, Miecznikowski A, Muzammil HS, Aadil RM. Khan MI, et al. Molecules. 2021 Nov 15;26(22):6881. doi: 10.3390/molecules26226881. Molecules. 2021. PMID: 34833974 Free PMC article. Review.

• In Vitro, In Silico Elucidation of Antiurease Activity, Kinetic Mechanism and COX-2 Inhibitory Efficacy of Coagulansin A of Withania coagulans.

  Phull AR, Hassan M, Abbas Q, Raza H, Haq IU, Seo SY, Kim SJ. Phull AR, et al. Chem Biodivers. 2018 Jan;15(1). doi: 10.1002/cbdv.201700427. Epub 2018 Jan 8. Chem Biodivers. 2018. PMID: 29121447